🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06776029
Recruiting Phase 2

Fecal Microbiota Transplantation for Radiation-Induced Proctopathy

NCT06776029 · tracked via the Priya Life Science China tracker
Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Phase
Phase 2
Started
2025-02-01
Last updated
2025-03-10

Condition(s) studied

Radiation Induced Proctitis

Investigational drug(s) / intervention(s)

Fecal Microbiota Transplantation Capsule

Fecal Microbiota Transplantation Capsule: FMT is delivered via oral capsules. Fecal microbiota capsules are given by 8 sessions over a 12-week period, with the initial 3 sessions every other day in the first week and the subsequent sessions every two weeks. The FMT regimen involves oral intake of 40 capsules per session. The best supportive care is performed when necessary, including oral medicine, enema, blood transfusion, and endoscopic procedures.

Study summary

The goal of this single-arm trial is to learn if Fecal Microbiota Transplantation (FMT) works to treat hemorrhagic radiation-induced proctopathy. The main questions it aims to answer are:

* Dose FMT alleviate the symptom of severe rectal bleeding?
* Dose FMT improve the endoscopic findings of proctopathy?

Participants will:

* Take fecal microbiota capsules by 8 sessions over a 12-week period.
* Visit the clinic once every 4 weeks for checkups and tests.
* Keep a diary of their symptoms and the number of times they use other supportive care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age: 18-75 years old * At least 3 months since the completion of pelvic radiotherapy * No evidence of tumor recurrence or metastasis * Rectal bleeding with grade 2-4 by LENT-SOMA scales * Colonoscopy indicating rectal congested mucosa or telangiectasia * Poor response to supportive care, or hemoglobin level less than or equal to 70 g/L in the past 3 months Exclusion Criteria: * Acute or chronic infectious diseases * Serious systemic diseases * Known allergies to any components of the study medication * Colonoscopy indicating rectal ulceration (\>1cm2), fistula, stricture, or necrosis * Late complications related to pelvic radiation injury * Other hemorrhagic or coagulation disorders * Previous rectal resection * Bowel obstruction or perforation that require surgery * Cognitive or psychological disorder * Contraindications to FMT administration

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Sixth Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong Recruiting

More Sixth Affiliated Hospital, Sun Yat-sen University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06776029 on ClinicalTrials.gov ↗ ← All trials in China